ADRIAN L. HARRIS, B.SC. D.PHIL.; DAVID SPENCE, B.SC.
To the editor: Weiss and Bruno's excellent review (1) does not mention hypersensitivity reactions to ellipticinium acetate (2 TV methyl 9-hydroxy ellipticinium acetate). This drug is undergoing phase II studies (Second NCI-EORTC Symposium on New Drugs in Cancer Therapy, Institute Jules Bordet, Brussels, 1979) and has an interesting spectrum of activity against tumours, including sarcomas, hypernephroma, and carcinoma of the breast (Second NCI-EORTC Symposium; ).
About 30% of patients receiving this drug develop specific IgM antibodies, mainly recognising the 9 hydroxy group (3). Five cases of intravascular haemolysis have been reported, and in one the patient had reversible renal failure,
HARRIS AL, SPENCE D. Reactions to Ellipticinium Acetate. Ann Intern Med. ;95:125. doi: 10.7326/0003-4819-95-1-125_2
Download citation file:
Published: Ann Intern Med. 1981;95(1):125.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use